Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
BriaCell Therapeutics ( (TSE:BCT) ) just unveiled an announcement.
BriaCell Therapeutics has released new imaging data from its Phase 2 study of Bria-IMT in heavily pre-treated metastatic breast cancer patients, showing regression and resolution of metastatic lesions in the eye orbit, temporal lobe of the brain, liver, and spine, as well as evidence of robust CD8+ T-cell activation and tumor infiltration. Among the 54 patients treated with the Bria-IMT regimen plus a checkpoint inhibitor, no treatment-related discontinuations have been reported to date, and several patients with extensive prior therapy remain alive beyond two years, underscoring the potential durability and safety of Bria-IMT as it progresses into a pivotal Phase 3 trial and potentially strengthens BriaCell’s position in the immuno-oncology landscape.
The most recent analyst rating on (TSE:BCT) stock is a Hold with a C$6.00 price target. To see the full list of analyst forecasts on BriaCell Therapeutics stock, see the TSE:BCT Stock Forecast page.
Spark’s Take on TSE:BCT Stock
According to Spark, TipRanks’ AI Analyst, TSE:BCT is a Neutral.
The score is held down primarily by weak financial performance (no revenue, widening losses, and significant cash burn with likely ongoing financing needs). Technicals are mixed with some shorter-term strength but negative MACD and a price still far below the 200-day average. Valuation contributes limited support due to a negative P/E and no dividend yield.
To see Spark’s full report on TSE:BCT stock, click here.
More about BriaCell Therapeutics
BriaCell Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies to transform cancer care, with a particular emphasis on metastatic breast cancer. Its lead program, Bria-IMT, is being advanced in combination with checkpoint inhibitors and has received Fast Track designation from the U.S. Food and Drug Administration, positioning the company within the competitive field of next-generation oncology treatments.
Average Trading Volume: 16,843
Technical Sentiment Signal: Sell
Current Market Cap: C$39.63M
See more data about BCT stock on TipRanks’ Stock Analysis page.